Halozyme Therapeutics (HALO) Tmuɣli n wazal
Halozyme Therapeutics
Ṛṛbem n lḥedd$113.91Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-1.14%
Asnulfu n AI: HALO
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Halozyme Therapeutics, Inc. is a biopharmaceutical company that produces treatments for diabetes, cancer, and skin diseases. The company focuses on developing new drug delivery methods. Its technology platform is based on recombinant human hyaluronidase and additional enzymes.
